Repligen
Executive Summary
Former Glaxo VP-Discovery Research Leslie Hudson, PhD, joins as chief operating officer, reporting to President and CEO Sandford Smith at the Cambridge, Mass. R&D company. Hudson was director of the Cancer and Hyperproliferative Disease Therapeutic Area at Glaxo in Research Triangle Park. He replaces John Kenward, who left Repligen in June